Figure 3From: Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adultsRelationship between 2-year expected cost and period of the PL ≥ 30 × 109/L. PL: platelet, SP: splenectomy, RO: romiplostim, RI: rituximab.Back to article page